These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3505838)

  • 21. Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.
    D'Andrea G; Perini F; Hasselmark L; Alecci M; Cananzi AR
    Funct Neurol; 1995; 10(2):91-8. PubMed ID: 7557557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time.
    Blaicher AM; Landsteiner HT; Zwerina J; Leitgeb U; Volf I; Hoerauf K
    Anaesthesia; 2004 Nov; 59(11):1100-3. PubMed ID: 15479319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a new non-steroidal anti-inflammatory agent, sulindac, on platelet function.
    Green D; Given KM; Ts'ao C; Whipple JP; Rossi EC
    Thromb Res; 1977 Feb; 10(2):283-9. PubMed ID: 322358
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles.
    Majerus PW; Stanford N
    Br J Clin Pharmacol; 1977 Feb; 4 Suppl 1(Suppl 1):15S-18S. PubMed ID: 406909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin as an antiplatelet agent.
    Shah R
    Arch Intern Med; 1980 Dec; 140(12):1676. PubMed ID: 7458507
    [No Abstract]   [Full Text] [Related]  

  • 26. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of platelet effect with the aspirin analog, salsalate.
    Estes D; Kaplan K
    Arthritis Rheum; 1980 Nov; 23(11):1303-7. PubMed ID: 7447965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity.
    O'Kane P; Xie L; Liu Z; Queen L; Jackson G; Ji Y; Ferro A
    Cardiovasc Res; 2009 Jul; 83(1):123-30. PubMed ID: 19377066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New derivatives of benzopyran-4-one with analgesic, anti-inflammatory and antiplatelet clumping activity].
    Darmanaden R; Dhanutirto H; Castel J; Loubatiere J; Flandre O
    Farmaco Sci; 1984 Oct; 39(10):876-87. PubMed ID: 6334617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.
    Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
    Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
    J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin resistance: does it exist and is it an important clinical problem?
    Eikelboom J
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):268-70. PubMed ID: 16728937
    [No Abstract]   [Full Text] [Related]  

  • 34. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of aspirin standard therapy and chronotherapy on circadian organization of hemocoagulation in patients with insulin-dependent diabetes mellitus].
    Zaslavskaia RM; Tulemisov EU; Teĭblium MM
    Klin Med (Mosk); 2002; 80(2):43-6. PubMed ID: 11898722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards a definition of aspirin resistance: a typological approach.
    Weber AA; Przytulski B; Schanz A; Hohlfeld T; Schrör K
    Platelets; 2002 Feb; 13(1):37-40. PubMed ID: 11918835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of aspirin and propranolol on feline platelet aggregation.
    Greene CE
    Am J Vet Res; 1985 Sep; 46(9):1820-3. PubMed ID: 3931514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of several non-steroidal anti-inflammatory and analgesic drugs on platelet granules under normal and leukemic conditions.
    Basu B; Ray B; Bhattacharya DK; Chatterjee GC
    Indian J Cancer; 1977 Jun; 14(2):141-4. PubMed ID: 303230
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.